Work

SPIRITT: A Randomized, Multicenter, Phase II Study of Panitumumab with FOLFIRI and Bevacizumab with FOLFIRI as Second-Line Treatment in Patients with Unresectable Wild Type KRAS Metastatic Colorectal Cancer

Year: 2015

Type: article

Study designs: Randomized Controlled Trial, Clinical Trial

Source: Clinical Colorectal Cancer

DOI: 10.1016/j.clcc.2014.12.009

Authors: J. Randolph Hecht, Allen Cohn, Shaker Dakhil, Mansoor Saleh, Bilal Piperdi, Mika Cline-Burkhardt, Ying Tian, William Y. Go

Institutions: University of California, Los Angeles, Rocky Mountain Cancer Centers, Cancer Center of Kansas, Georgia Cancer Specialists, Montefiore Medical Center, Texas Oncology, Amgen (United States)

Language: English

Topic: Colorectal Cancer Treatments and Studies

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funder: Amgen

OpenAlex ID: W2011349651

FWCI: 6.243

Cites: 25

Cited by: 115

Related to: 10